Naviscan takes hi-res PET scanner forward with $6.5m financing:
This article was originally published in Clinica
Executive Summary
A private San Diego, California-based developer of high resolution PET imaging systems, Naviscan PET Systems, has raised $6.5m in a second round of financing led by Sanderling Ventures and included the participation of Mayo Medical Ventures. The funds will be used to commercialise Naviscan's PEM Flex Solo PET scanner, as well as to develop proprietary molecular imaging agents, licensed from Mayo Clinic, for use in conjunction with the device to aid early detection of cancers. Cleared by the US FDA in September 2003, the PEM Flex system is designed to guide challenging radiological and surgical procedures and minimally-invasive therapy in the breast and prostate.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.